Appendix: Ongoing trials assessing maintenance strategies

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Trial identification | Title | Design | Investigational treatment | Remarks |
| NCT03778996 | SM-88 as maintenance therapy for advanced Ewing’s sarcoma patients and as salvage therapy for sarcoma patients (HopES) | Stratified non-randomized phase 2 trial | Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus | Switch maintenance therapy after standard therapy |
| NCT03719430 | APX005M and doxorubicin in advanced sarcoma | Non-randomized phase 2 trial | CD40 agonistic monoclonal antibody | Continuation of maintenance therapy after eight cycles of doxorubicin |
| NCT03420014 | A randomized study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma | Randomized phase 2 trial | Cytokine fusion protein L19TNF agonistic monoclonal antibody | Continuation of maintenance therapy after doxorubicin |
| NCT03624244 | Randomized comparative prospective multicentre phase II trial evaluating clinical impact of interruption vs maintenance of AI in patients with locally advanced/metastatic LGESS | Randomized phase 2 trial | Aromatase inhibitor |  |
| NCT02367651 | A randomized, double-blind, placebo-controlled phase II study of pazopanib versus placebo as maintenance therapy for patients who have not progressed after first-line chemotherapy for advanced soft tissue sarcoma (STS) | Randomized phase 2 | Pazopanib, a multikinase inhibitor | Closed before enrolment of any participants |
| NCT04055220 | A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bone sarcomas | Randomized phase 2 trial | Regorafenib, a multikinase inhibitor | Switch maintenance therapy |
| NCT02207309 | A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior neo- and/or adjuvant doxorubicin/ifosfamide chemotherapy with regional hyperthermia | Randomized phase 2 trial | Pazopanib, a multikinase inhibitor | Switch maintenance therapy, closed to recruitment |
| NCT02929394 | Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma | Randomized phase 2 trial | Trabectedin, chemotherapy agent | Closed due to low accrual |
| NCT03793361 | Efficacy of regorafenib as maintenance therapy in non-adipocytic soft tissue sarcoma having received first-line doxorubicin-based chemotherapy | Randomized phase 2 trial | Regorafenib, a multikinase inhibitor |  |
| NCT00923936 | Pilot study of liposomal doxorubicin combined with bevacizumab followed by bevacizumab monotherapy in adults with advanced Kaposi sarcoma | Non-randomized phase 2 trial | Bevacizumab, anti-VEGFR antibody | Closed to recruitment – final results posted |
| NCT02997358 | Randomised phase III multicentric study comparing efficacy of doxorubicin with trabectedin followed by trabectedin in non-progressive patients versus doxorubicin alone as first-line therapy in patients with metastatic or unresectable leiomyosarcoma (uterine or soft tissue) | Phase 3 trial | Trabectedin, chemotherapy agent | Continuation of maintenance therapy. Recruitment completed. |
| NCT03063983 | A study multicenter randomized to assess the efficacy and toxicity of adding metronomic therapy to the standard treatment of patients with high grade malignant osteosarcoma with metastatic lung disease at diagnosis and primary resectable tumor: A study by the Latin American Group for Treatment of Osteosarcoma | Phase 3 trial | Metronomic chemotherapy | Switch maintenance therapy – accrual completed |